FIELD: medicine.
SUBSTANCE: method involves determining thyroxin hormone concentration in cerebral metastasis-ill patient blood prior to treatment beginning. Its concentration being found within the limits of 68.0-115.0 nmole/l, 1 to 3 metastatic lesion foci are predicted to be available. The concentration being from 38.0 to 50.0 nmole/l, more than 4 p metastatic lesion foci are predicted to be available.
EFFECT: high forecasting accuracy both in primary examination period, and when carrying out treatment.
1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING EXTRACRANIAL METASTASES DEVELOPMENT IN PATIENTS HAVING METASTASES IN BRAIN | 2005 |
|
RU2297005C1 |
| METHOD FOR DETECTING EXTRACRANIAL METASTASES IN METASTATIC BRAIN INJURY PATIENTS | 2005 |
|
RU2300110C2 |
| METHOD FOR PREDICTING BRAIN METASTATIC INJURIES GENERALIZATION | 2005 |
|
RU2300104C2 |
| METHOD FOR TREATING ONCOLOGICAL PATIENTS WITH METASTATIC CEREBRAL LESION | 2005 |
|
RU2290974C1 |
| METHOD OF PREDICTING CHEMORADIOTHERAPY EFFICIENCY IN PATIENTS WITH DISSEMINATED SKIN MELANOMA | 2008 |
|
RU2398238C1 |
| METHOD FOR PREDICTING EFFICIENCY OF AUTOHEMOCHEMOTHERAPY IN PATIENTS WITH CANCER OF MOUTH CAVITARY AND PHARYNGEAL ORGANS | 2003 |
|
RU2253354C2 |
| METHOD FOR PREDICTING RELAPSE OF MAMMARY CANCER | 2003 |
|
RU2263319C2 |
| METHOD FOR PREDICTING METASTASIS AND FLOW OF TUMOR PROCESS IN PATIENTS WITH PULMONARY CANCER | 2002 |
|
RU2214605C1 |
| METHOD FOR TREATING CEREBRAL METASTASES OF GENERALIZED SKIN MELANOMA | 2005 |
|
RU2286146C1 |
| METHOD FOR PREDICTING INDIVIDUAL TUMOR SENSITIVITY TO CHEMOTHERAPY | 2000 |
|
RU2179725C2 |
